Healthcare Industry News: Pegasus Biologics
News Release - February 14, 2006
Pegasus Biologics, Inc. Introduces the OrthADAPT(TM) Bioimplant -- A Revolutionary New Biologic Scaffold for Orthopedic Soft Tissue ReinforcementIRVINE, Calif.--(HSMN NewsFeed)--Feb. 14, 2006--Pegasus Biologics, Inc., developers of novel Bioimplants for soft tissue repair, announced it has commercially launched the OrthADAPT(TM) Bioimplant -- a biocompatible, stabilized, terminally sterilized collagen scaffold that fortifies and promotes tissue ingrowth for long-term performance. The OrthADAPT Bioimplant is intended for use in the reinforcement, repair and reconstruction of soft tissue in musculoskeletal procedures. Developed over time and proven in preclinical studies, Pegasus Biologics' breakthrough technologies provide the Bioimplant with unique advantages in biocompatibility and reliability.
"We are extremely pleased with the OrthADAPT Bioimplant's reception from our valued implanting surgeons," expressed Keegan Harper, Chairman and CEO. "They are particularly impressed with the Bioimplants' strength, handling characteristics; and versatility allowing them to use it for both routine and challenging repairs."
Chris Young, MD, a renowned orthopedic surgeon at Chippenham Hospital (Richmond, VA) is very pleased with his early results with the OrthADAPT Bioimplant. "I have used the Bioimplant for both rotator cuff repair and anterior shoulder reconstruction and in both cases the patients are recovering extremely well." Dr. Larry Lemak, St. Vincent's Hospital, (Birmingham, AL), the first OrthADAPT implanter states, "I am delighted with the way the Pegasus Bioimplant handled during surgery. It was technically very easy to use, held sutures well and demonstrated good tension. I was able to incorporate the Bioimplant into the defect site, not just lay it on top."
Al Weinstein, Executive VP of Sales and Marketing, is very optimistic about the future of the OrthADAPT Bioimplant. "Surgeons have been waiting for a biologic collagen implant that they can rely on for long-term performance. Preclinical studies have shown that the Bioimplant undergoes controlled remodeling which will make it a reliable scaffold over time."
The OrthADAPT Bioimplant is being distributed domestically through a seasoned independent distribution network.
Pegasus Biologics, Inc. manufactures, sterilizes and markets specialized, advanced Bioimplants for use in orthopedic musculoskeletal applications. For more information about Pegasus Biologics, visit our website at www.pegasusbio.com or contact France Dixon Helfer, President, at 949.502.3240 x201.
This press release contains forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, regulatory approvals, clinical results, intellectual property, competitive offerings, the Company's overall business strategy, and other factors described in the Company's Business Plan.
Source: Pegasus Biologics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.